The mutation rate of the Omicron sublineage has led to baseline resistance against all
previously authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more …

Convalescent plasma has been extensively tested during the COVID-19 pandemic as a
transfusion product. Similarly, monoclonal antibodies have been largely administered either …

Objectives Immunocompromised patients have an increased risk of severe or prolonged
COVID-19. Currently available drugs are registered to treat COVID-19 during the first 5 to 7 …

The COVID-19 pandemic accelerated research and innovation across numerous fields of
medicine. It emphasized how disease concepts must reflect dynamic and heterogeneous …

Solid organ transplant (SOT) recipients receive immunosuppressive drugs (ISDs) and are
susceptible to developing severe COVID-19. Here, we analyze the Spike-specific T-cell …

Despite such evidence, the interest towards the production and clinical use of CCP has
progressively declined since early 2021, due to the marketing of anti-Spike monoclonal …

Solid organ transplant recipients (SOTRs) are at high risk for infections including SARS-CoV-
2, primarily due to use of immunosuppressive therapies that prevent organ rejection …

Objectives Due to the rapid evolution of SARS-CoV-2 to variants with reduced sensitivity to
vaccine-induced humoral immunity and the near complete loss of protective efficacy of …

Monoclonal antibody (mAb) therapeutics hold promise for both preventing and treating
infectious diseases, especially among vulnerable populations. However, the emergence of …

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), emerged in 2019 following prior outbreaks of coronaviruses like SARS and …